Patients with corneal damage and considerable vision loss had biosynthetic corneas implanted into their eyes with FibroGen's proprietary rhCIII (recombinant human type III collagen), which restored their vision and promoted nerve regeneration. A report on this 2-year Phase I clinical trial has been published in the peer-reviewed journal Science Translational Medicine. The authors explain that damage to the cornea and corneal disease are major causes of blindness globally. Some countries have cornea tissue banks - corneas are collected from human Read from Source
